R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008

12-Mar-2009 - New statistics just released reveal that R&D investment in new medicines by the biopharmaceutical industry was $65.2 billion in 2008, an increase of 3 percent from 2007, according to a combined analysis conducted by Burrill & Company and the Pharmaceutical Research and Manufacturers of America ...

R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007

26-Mar-2008 - New statistics just released reveal that R&D investment in new medicines by the biopharmaceutical industry was $58.8 billion in 2007, according to a combined analysis conducted by Burrill & Company. PhRMA-member (Pharmaceutical Research and Manufacturers of America) companies alone spent an ...

Biotech has Positive Year Despite Weak Fourth Quarter Performance

Burrill looks back at 2007

04-Jan-2008 - "The biotech industry finished the year in good shape with the Burrill Biotech Select Index, a price-weighted index tracking 20 of biotech's "blue chip" companies, gaining 9% in 2007 ahead of the Dow, which finished up 6.4% and on par with the Nasdaq, which closed up 9.8%," said G. Steven ...

Biotech Survives Market Turbulence in November

10-Dec-2007 - Wall Street closed out a volatile month and although the Dow ended the final week of November with gains, it still posted a 4% decline for November. This was even in wake of its biggest percentage gain in four and a half years during the month. "Investors remained extremely nervous about ...

Biotech Weathers a Market Storm in February

06-Mar-2007 - While the 416-point plunge in the Dow industrials on the penultimate day of the month took the wind out of biotech's sails, which up until then was performing ahead of the general markets, it did not completely ruin what was a strong performance by biotechs. The Burrill Biotech Select Index held ...

Biopharmaceutical Industry Research & Development Tops $55 Billion In 2006

15-Feb-2007 - New statistics just released reveal that R&D investments in new medicines by the biopharmaceutical industry was over $55 billion in 2006, according to a combined analysis conducted by Burrill & Company and the Pharmaceutical Research and Manufacturers of America (PhRMA). "This is the third year ...

It's Halloween ... Biotech Market Spooked in October

Market downturn catches biotech in its wake

02-Nov-2004 - "The biotech market took a beating in October, partly because of the general public market experiencing pre- election jitters, partly in reaction to Merck's Vioxx withdrawal and partly because Chiron, one of the five top biotech firms in the country, lost nearly a third of its value over the flu ...

Biotech's Getting Back on Track

G. Steven Burrill's 18th Annual Report on the biotech industry's released

05-Mar-2004 - San Francisco. Biotech staged a spectacular comeback in 2003, rekindling enthusiasm on Wall Street and turning in the industry's second best year. 2003 was a year of getting "back on track" for biotech; its market capitalization rose by 53%. A much improved FDA approved some 25 new biotech ...

Biotech Honors the Best of 2003

Outstanding Products, Companies, Individuals, and Business Strategies Are Honored by Peers

28-Oct-2003 - Winners of the Best of Biotech 2003 awards and inductees into the Biotech Hall of Fame were announced Sunday night, October 12, at the 16th Annual Biotech Meeting at Laguna Niguel, a biotech CEO-only conference hosted by Burrill & Company and Kleiner Perkins Caufield & Byers. For a decade and a ...